Objective: Glucosamine (GLN) and chondroitin sulfate (CS) are widely used to alleviate symptoms of osteoarthritis (OA). However, the mechanism(s) of action of these nutraceuticals remains unresolved. In the present study, we determined the effect of physiologically relevant concentrations of GLN and CS on gene expression and synthesis of nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) in cytokine-stimulated articular cartilage explants.
Introduction
Osteoarthritis (OA) is characterized by the degeneration of matrix components of articular cartilage accompanied with an excess production of proinflammatory cytokines 1 . Interleukin-1 (IL-1) beta is widely accepted as one of the proinflammatory cytokines that plays a pivotal role in the pathophysiology of OA 2 . It induces a cascade of catabolic events in chondrocytes including the up-regulation in genes of matrix metalloproteinases (MMPs), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGEs1) and the release of nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) 3e6 . IL-1 also retards anabolic activities of the chondrocytes leading to declines in proteoglycan synthesis and collagen synthesis 7, 8 .
NO is produced from L-arginine catalyzed by a family of NO synthases 9e11 . The constitutive isoforms are endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS). An elevated level of iNOS is responsible for the secretion of NO, an inorganic free radical, in large amount from OA cartilage. NO oxide promotes inflammation and articular cartilage degeneration by increasing cytokine production, suppressing matrix synthesis, elevating MMPs and inactivating tissue inhibitors of metalloproteinases (TIMPs) 12e14 . PGE 2 mediates inflammatory and pain responses, and is the most abundant prostanoid found in the diseased joint 15 . COX and PGE synthases are rate-limiting enzymes responsible for generating PGE 2 . The inducible form of this enzyme is COX-2, which catalyzes the conversion of arachidonic acid to prostaglandin H 2 (PGH 2 ) and mPGEs1, which isomerizes PGH 2 to PGE 2 . The synthesis of PGE 2 correlates with up-regulation of COX-2 and mPGEs1 6, 16 . PGE 2 elicits its catabolic effect on articular cartilage by enhancing MMP production and proteoglycan degradation and by inhibiting synthesis of TIMPs 17, 18 .
Various compounds have been used in palliative treatment of OA. Two compounds that are increasing in favor as a treatment option for joint diseases both in humans and animals are glucosamine (GLN) and chondroitin sulfate (CS). These compounds are termed nutraceuticals because they have both nutrient and pharmaceutical properties. They have been used over the past 30 years for the treatment of OA and shown in several animal and human studies to be beneficial in reducing articular cartilage degeneration, pain, and inflammation. In animals, the combination reduces lameness in dogs and horses and is effective in managing pain in cats 19e21 . GLN and CS used alone or in combination can decrease joint space narrowing, alleviate pain, and improve joint mobility in humans affected with knee OA 22e25 .
Elucidating the mechanism(s) of action of GLN and CS in vivo is an active area of research. Pain amelioration with GLN and CS may be attributed to a reduction in inflammatory mediators. In vitro, cytokine-stressed cartilage explants treated with GLN demonstrated a decline in iNOS transcript and NO release into the media 26e30 . Parallel with the inhibition of COX-2, PGE 2 production and release was also inhibited with GLN 26, 28, 31 . CS possesses anti-inflammatory properties 32 .
To date, the majority of in vitro research has been performed with concentrations of GLN and CS that exceed those likely to be obtained by oral administration 26e28,31,33e35 . This was one of the reasons given by rheumatologists in their objection to recommending GLN to patients 36 . The concentrations of GLN in serum after oral and intravenous administration range from 1 to 20 mg/ml while CS concentrations are in the 5e200 mg/ml range depending on the route of administration, species and the molecular weight of CS 37e42 . Thus, the aim of the present study was to determine the effect of concentrations of GLN (5 mg/ml) and CS (20 mg/ ml) that have been attained in blood on mRNA expression of iNOS, eNOS, COX-2 and mPGEs1 and the production of NO and PGE 2 in articular cartilage explants stimulated with IL-1, a cytokine associated with cartilage catabolism.
Materials and methods

EXPLANT CULTURES
Articular cartilage was isolated from the carpal joints of Holstein steers (18e24 months old) obtained from a local abattoir within 3 h of slaughter. Cartilage discs (6 mm) were biopsied from the articular surface and did not include cartilage with gross characteristics of OA and calcified cartilage. Two explant discs (approximately 60 mg total wet weight) were randomly picked and cultured in each well of a 24-well Falcon culture plate (Fisher Scientific, Pittsburgh, PA, USA) containing 1 ml of 1:1 modified version of Dulbecco's modified Eagle's medium:nutrient mixture F-12 (Ham) (Gibco, Grand Island, NY, USA), as previously described 27 . The media were supplemented with 20 amino acids (Sigma, St. Louis, MO, USA), 50 mg/ml ascorbic acid, and 100 units/ml penicillin/streptomycin (Gibco). The concentrations of amino acids added were 50% of those previously reported 43 . Cartilage explants were housed in a humidified incubator at 37(C with 7% CO 2 .
Explants were maintained in media without serum for 2 equilibration days prior to the addition of treatments. After equilibration, all treatments received 10% fetal bovine serum (FBS, Gibco) and 50 ng/ml of human recombinant IL-1 beta (rhIL-1b, R & D Systems, Minneapolis, MN, USA) added to induce cartilage catabolism. The concentrations of GLN HCl (5 mg/ml; FCHG49 Ò , Nutramax Laboratories, Edgewood, MD, USA) and low molecular weight (16.9 kDa) CS (20 mg/ml; TRH122 Ò , Nutramax Laboratories) chosen were well within the range of levels measured in the blood 37, 41 . There were five treatments per experiment (Table I) , an FBS control (Ctrl), 50 ng/ml rhIL-1b (IL-1), 50 ng/ml rhIL-1b with the addition of 5 mg/ml GLN (IL-1 C GLN), 50 ng/ml rhIL-1b with the addition of 20 mg/ml CS (IL-1 C CS) and 50 ng/ml rhIL-1b with the addition of both GLN and CS (IL-1 C GLN C CS). Each treatment consisted of 24 discs (12 wells) collected from a pool of three steers for an experiment. Cartilage discs were collected 6, 24 and 48 h post-stimulation, frozen in liquid nitrogen and stored at ÿ80(C until RNA isolation. Conditioned media were collected at 24 and 48 h and stored at 4(C for nitrite and PGE 2 analysis. Experiment was repeated a total of three times for each time point, each time using tissue from a pool of three different animals.
NO ASSAY
Nitrite is a stable end product of NO metabolism and was measured in conditioned media using the Griess reagent and sodium nitrite as standard 44 . Briefly, 150 ml medium was incubated with 150 ml of 1.0% sulfanilamide, 0.1% N-1napthylethylenediamide hydrochloride and 25% phosphoric acid at room temperature for 5 min. Due to some precipitation of reagents with CS, 96-well plates were spun at 3250 rpm for 3 min at 4(C. The remaining supernatant was transferred to a new plate. Absorbance was measured at 540 nm using a Spectromax 300 plate reader (Molecular Devices, Sunnyvale, CA, USA). PGE 2 ASSAY PGE 2 release into conditioned media was quantified using a commercially available competitive enzyme linked immunosorbent assay kit (R & D Systems). Indomethacin (10 mg/ml) was added to conditioned media samples collected at 24 and 48 h post-stimulation to inhibit any prostaglandin synthase present, and stored at ÿ20(C until analysis. Samples were run according to the manufacturer's instructions. Absorbance was determined at 405 nm with a wavelength correction set at 590 nm.
TOTAL RNA ISOLATION
The extraction of RNA from explants was performed following a modified protocol 45 . Briefly, cartilage was homogenized in TRIzol Ò reagent (Invitrogen, Carlsbad, CA, USA), chloroform was added to extract total RNA followed by vigorous agitation and a 2 min incubation. The aqueous phase containing RNA was collected after centrifugation and the RNA was precipitated with ethanol. Total RNA was then purified further with RNeasy mini columns (Qiagen, Valencia, CA, USA) and quantified by UV spectrophotometry (Beckman Coulter, Fullerton, CA, USA). Total chondrocyte RNA was resolved on 1.2% agarose gel to validate spectrophotometric determinations and RNA integrity.
CDNA SYNTHESIS
For each sample, 2 mg of RNA was treated with DNase I (Invitrogen) to degrade contaminating single and double Primers for glyceraldehyde phosphate dehydrogenase (GAPDH, used as a housekeeping gene) and molecules from Table II were designed using the Primer Express software version 2.0 (Applied Biosystems, Foster City, CA, USA). Optimal concentrations of each set of primers were determined with a Primer Matrix (lowest standard deviation with no change in cycle to threshold (Ct)). Q-RT-PCR was performed with 50 ng cDNA templates in 96-well plates using the ABI PRISM 7000 sequence detection system (Applied Biosystems). The analysis of each sample was performed in duplicate. The cDNA templates were combined with optimal concentrations of primers and SYBR Green PCR dye mix (Applied Biosystems) in a total volume of 50 ml and the amplification conducted as recommended by manufacturer.
The PCR conditions were 2 min at 50(C and 10 min at 95(C followed by 40 cycles of extension at 95(C for 15 s and 1 min at 60(C, and data collected during the last 30 s. Threshold lines were adjusted to intersect amplification lines in the linear portion of the amplification curves. The software automatically recorded the Ct. The GAPDH gene was used as an endogenous control and run together with the samples for each amplification reaction to allow for normalization of different samples for RNA loading, cDNA synthesis, and amplification efficiencies and for comparison of samples run at different times. The FBS control was used as a calibrator (i.e., the fold change for control is 1.0). Replicated data were normalized with GAPDH and the fold change in gene expression relative to FBS control treatment was calculated using the delta delta Ct method 46 .
STATISTICAL ANALYSIS
Data for NO and PGE 2 release into conditioned media were analyzed using a linear mixed effects model, including the fixed effect of treatment and the random effects of pool, the interaction between treatment and pool, and repeated measures within each treatment and pool combination. Treatment effects were compared within each time point using the multiple comparisons approach of Tukey. The computations were performed using the MIXED procedure of SAS 47 . Relative gene expression data determined using Q-RT-PCR were analyzed considering the nonparametric ANOVA approach of Friedman 48 . Differences were declared statistically significant when P ! 0.05, unless otherwise noted. Spearman's rank correlations (r) between gene expression data and biochemical data were computed using the CORR procedure of SAS 47 .
Results
THE EFFECT OF GLN AND CS ON GENE EXPRESSION
Bovine articular cartilage explants cultured with 50 ng/ml rhIL-1b for 6, 24 and 48 h resulted in significant (P ! 0.01) up-regulation of iNOS expression relative to control (Table  III) . The large standard error for both IL-1 and IL-1 plus CS treatments at 6 h was attributed to variation between pools of animal tissue and not technical error within a replication. GLN (5 mg/ml) down-regulated iNOS mRNA expression from 11.1fold to 4.5-fold in explants cultured for 24 h (Table III) . CS (20 mg/ml) added alone or in combination with GLN for 24 h was as effective as GLN in suppressing iNOS transcripts (Table III) but only the combination reduced iNOS expression to control levels. After 48 h, cytokine-stimulated explants treated with CS or GLN and CS repressed iNOS mRNA expression to control levels (Table III) . The iNOS transcript of explants treated with GLN alone at the 48 h time point was not different from IL-1 stimulated explants (Table III) .
Cartilage explants stimulated with 50 ng/ml rhIL-1b demonstrated significant elevation in COX-2 mRNA expression relative to control by 30-fold for 6 h poststimulation (Table III) IL-1 Z 50 ng/ml rhIL-1b; IL-1 C GLN Z 50 ng/ml rhIL-1b and 5 mg/ml GLN; IL-1 C CS Z 50 ng/ml rhIL-1b and 20 mg/ml CS; IL-1 C GLN C CS Z 50 ng/ml rhIL-1b, 5 mg/ml GLN and 20 mg/ml CS. Different superscripts for values within a row (i.e., one gene) denote a significant difference (P ! 0.05) between treatments.
389
Osteoarthritis and Cartilage Vol. 13, No. 5 resulted in a decline of COX-2 transcripts to control levels (Table III) . The COX-2 gene for explants treated with 50 ng/ml rhIL-1b was significantly up-regulated by 8-fold and 13-fold for 24 and 48 h post-stimulation, respectively (Table III) . At both time points, GLN suppressed the activation of the COX-2 gene to control levels (Table III) . Physiologically relevant concentration of CS at 20 mg/ml did not repress COX-2 transcript increased by IL-1 until 48 h (Table III) . The GLN and CS combination decreased COX-2 expression to 3.4-fold and 1.0-fold change for 24 and 48 h, respectively (Table III) , which is not different from control.
The transcript for mPGEs1, the terminal enzyme involved in PGE 2 synthesis was elevated by about 9-fold (P Z 0.0008) relative to control, in explants cultured with 50 ng/ml rhIL-1b over a 6-h period (Table III) . At this time point, GLN alone and the nutraceuticals combination repressed mPGEs1 mRNA expression to control levels (Table III) . No effect on mPGEs1 expression was found for any of the treatments at 24 and 48 h (Table III) .
THE EFFECT OF GLN AND CS ON NO AND PGE 2 SYNTHESIS
NO released into conditioned media at 24 h after the addition of treatment was increased with 50 ng/ml rhIL-1b to 21.39 mM from 5.98 mM for FBS control [ Fig. 1(A) ]. The addition of CS or GLN plus CS suppressed NO release to 16.93 and 17.27 mM, respectively [ Fig. 1(A) ]. At 48 h, the elevation in NO release with 50 ng/ml rhIL-1b was not reduced by either nutraceutical [Fig. 1(B) ].
Explants stimulated with 50 ng/ml rhIL-1b released significantly more PGE 2 into media when compared to control. After 24 h stimulation, PGE 2 release was elevated to 1986 pg/ml compared with basal PGE 2 release at 169 pg/ml [ Fig. 2(A) ]. The addition of GLN and CS, or in combination reduced PGE 2 release induced by cytokine to control levels [ Fig. 2(A) ]. The basal PGE 2 release into media 48 h post-treatment was 171 pg/ml [ Fig. 2(B) ]. This level was elevated to 1122 pg/ml when 50 ng/ml rhIL-1b was added [ Fig. 2(B) ]. GLN decreased PGE 2 release due to IL-1 by 68% [ Fig. 2(B) ]. Likewise, the combination resulted in a 76% decline in PGE 2 release induced by IL-1 [ Fig. 2(B) ]. CS addition to the explants in vitro tended (P ! 0.10) to decrease PGE 2 release [ Fig. 2(B) ].
THE EFFECT OF GLN AND CS ON ENOS GENE EXPRESSION
Since the biochemical data on NO release conflicted with the Q-RT-PCR data on iNOS gene expression profile, we decided to investigate the expression of the eNOS gene, another isoform of the NO synthase enzyme. Only a transient pattern of eNOS regulation by CS was witnessed. The IL-1 mediated increase in eNOS transcript of 3.3-fold at 24 h was significantly (P ! 0.05) reduced to 0.3-fold with 20 mg/ml CS. No significant differences were seen with the other treatments (data not shown). 
Discussion
To our knowledge, the present study is the first to describe the effect of GLN and CS attained in blood on gene expression and synthesis of inflammatory mediators using a cartilage explant culture. The concentration chosen for GLN was 5 mg/ml while that for CS was 20 mg/ml. These concentrations were at the low end of the range found in blood after oral or intravenous administration 37, 41, 42 . Previous trials from our laboratory used concentrations which are higher than the range found in the plasma of animals administered GLN and CS 49 . Another novelty of this research lies in the nutraceutical combination investigated. Few in vitro studies have been conducted with the GLN and CS combination although they are frequently marketed as a combination. One study reported that they are synergistic 50 , while another suggested they may be complementary 49 .
NO is implicated in the pathogenesis of arthritis. Normal cartilage explants produce little NO 51 . On the contrary, chondrocytes and the synovial membrane in OA and rheumatoid arthritis (RA) patients produce NO abundantly and so does cytokine-induced cartilage 51e53 . In fact, activated articular chondrocytes produce more NO than any other cells, including synoviocytes, hepatocytes and macrophages 3 . Inducible forms of NO synthase are found in cartilage and produce large amounts of NO in response to IL-1 13 . Both iNOS mRNA and protein concentrations are higher in OA cartilage relative to healthy articular cartilage and increase with severity of the degenerative joint disease 54 . The ability of IL-1 to enhance iNOS transcript was also evident in the present study (Table III) 3 . NO suppresses proteoglycan synthesis by inhibiting the process of sulfation on the glycosaminoglycan chains 14, 55 . Inhibition of prolyl hydroxylase coupled with the suppression of type II collagen synthesis was associated with the release of large amounts of NO 56 . This inorganic free radical also mediates the degradation of matrix components via activation of MMPs 13 . Besides cartilage destruction, NO has also been implicated as a mediator of inflammatory responses 12 . Thus, the inhibition of NO synthesis may be effective as a therapeutic route for OA. GLN and CS have been used successfully for treating chronic inflammatory arthritides. One of the mechanisms of action of these compounds may be the suppression of NO production. Previous work from our laboratory using explants from horses indicates decreased NO production with 250 mg/ml CS and with the combination of 500 mg/ml GLN and 250 mg/ml CS 49 . Inhibition of NO with GLN occurred at concentrations greater than 1 mg/ml in equine explants and human chondrocytes 27, 30, 49 . Suppression of NO synthesis with GLN was associated with iNOS mRNA and protein repression 29, 30 . In the current trial, CS alone and in combination with GLN at physiological concentrations were effective in reducing NO synthesis induced by IL-1 at 24 h [ Fig. 1(A) ]. At 48 h of culture, nitrite has accumulated to the same level for all treatments except for control [ Fig. 1(B) ]. These levels of NO in conditioned media may be explained by transcriptional regulation of genes pertaining to the enzymes responsible for synthesizing NO. Although the levels of NO were significantly reduced at 24 h, these were marginal declines. Since NO and PGE 2 can modulate the activity of the other 57 , even transient regulation of NO may affect the anti-inflammatory response to some extent.
The inducible form of the NO synthases is iNOS and there are two constitutive isoforms, eNOS and nNOS. The constitutive form of eNOS was initially thought to be confined to endothelial cells while nNOS was localized to the central and autonomic nervous systems 9 . However, eNOS and nNOS have increasingly been identified in a lot of different cell types including chondrocytes 58 . eNOS may also be inducible since human eNOS gene contains activator protein-1 (AP-1) site in its promoter region 59 . The mitogen-activated protein kinase (MAPK) pathway is activated by cytokines leading to AP-1 phosphorylation and up-regulation of a number of genes associated with cartilage catabolism 60 . Human OA chondrocytes express elevated levels of nNOS 61 . To date, only the genes for iNOS and eNOS and not nNOS in the bovine species have been cloned and sequenced. Since eNOS mRNA levels were not markedly affected at 48 h, the lack of treatment effect on NO production could be in part due to the activity of eNOS and potentially nNOS. PGE 2 , another catabolic mediator in the pathogenesis of OA is formed from a series of enzymatic reactions termed the arachidonic acid cascade. It mediates synoviocyte proliferation and is responsible for pain and inflammatory responses. PGE 2 enhances the degradative processes of proteoglycans 17, 18 . It is found in diseased joints and is significantly elevated in synovial fluid of OA patients 15, 18 . Large amounts of PGE 2 are synthesized by chondrocytes that are exposed to IL-1 in vitro 18 . Bovine explant cultures induced with IL-1 demonstrated significant increase in PGE 2 from basal levels [ Fig. 2(A,B) ]. Elevated levels of PGE 2 depleted matrix components from intact articular cartilage cultured in vitro 62 .
The induction of COX-2 is largely responsible for elevated concentrations of PGE 2 31,63 . COX-2 expression is elevated in cartilage specimens of OA and RA patients 64, 65 . Findings from the present study demonstrated the significant upregulation of the COX-2 gene relative to control in response to IL-1 for all time points (Table III) in accord with previous reports 31, 66 . Levels of PGE 2 in our explant cultures were positively correlated with COX-2 mRNA (r Z 0.81, P ! 0.0001) in agreement with Geng et al. 66 . Inhibiting PGE 2 release is an increasingly common strategy for providing relief to patients affected with arthritis as evidenced by the development of COX-2 inhibitors.
In clinical studies, GLN and CS have been consistently beneficial in improving the pain scores and inflammatory responses of patients affected with OA 22e25 . In vitro results from previous work in our laboratory and others demonstrated declines in the inflammatory mediator, PGE 2 , with GLN and CS supplementation 26, 31, 49, 67 . In the present study, GLN, CS alone or in combination reduced IL-1 induced PGE 2 levels. The ability of GLN and CS to reduce PGE 2 synthesis in the present study can be explained by their effect on COX-2 gene expression. Since there is a lag time of about 12e18 h from the time the gene is expressed to the time it is translated into protein, the COX-2 mRNA data at 6 h does correspond to the PGE 2 levels at 24 h while mRNA data at 24 h has a similar profile with PGE 2 levels at 48 h. The ability of GLN to suppress COX-2 mRNA expression by about 2-fold at 24 h post-stimulation parallels the work by Largo et al. 31 in human chondrocytes. However, the concentration of GLN used in their study was 1 mg/ml which is 200 times the concentration used in our study. The present study substantiates the claim that repression of COX-2 transcripts and eventually PGE 2 is at least one of the mechanisms GLN alone or together with CS exert their analgesic effects.
The effect of these chondroprotective agents on terminal PGE enzymes involved in the formation of PGE 2 has not been reported. In fact, we only know of one abstract that has investigated this enzyme in chondrocytes 68 . There are reports of concomitant regulation of COX-2, mPGEs1 and PGE 2 16, 68 . Transcripts of COX-2 and mPGEs1 are correlated in the present study (r Z 0.43, P ! 0.05). However, differences in the timing for COX-2 and mPGEs1 induction may be due to dissimilar regulatory sequences in these two genes 6 . Explants treated either with GLN alone or in combination with CS repressed IL-1 induced mPGEs1 expression at 6 h post-culture (Table III) . Further studies on the contribution of this brief regulation on mPGEs1 in chondrocytes by the nutraceuticals are warranted.
Determining the mechanism of action behind GLN and CS is essential to elucidating the beneficial effects elicited by these compounds in combating arthritic symptoms. Understanding how these agents may regulate NO and PGE 2 is an active area of research. Besides being proinflammatory, NO and PGE 2 have the ability to increase proteoglycan loss and decrease proteoglycan synthesis 14, 18 . Our results suggest a transient modulation of mPGEs1 and NO synthase gene expression, and NO synthesis by the nutraceuticals. Physiologically relevant concentrations of GLN and CS repress COX-2 expression that eventually translates into accompanying declines in PGE 2 synthesis. Thus, the findings in the present study may explain at least in part how IL-1 induced proteoglycan breakdown and decreased proteoglycan synthesis is prevented in vitro 69, 70 .
Results from the present study indicate that GLN and CS may regulate the expression and synthesis of NO and PGE 2 , providing a plausible explanation for the symptomatic relief attributed to the administration of these compounds.
